RE:RE:Zenith Update PerspectivesJk,
Zenith Epigenetics Corp right now holds both technology assets (their 1500 BET inhibitor library and other technology) and the RVX-208 Royalty Preferred Shares that came from the original 2013 Zenith spin-off. After the re-organization, the royalties will be held by Zenith Capital Corp and will be separate from the technology held by Zenith Epigenetics Ltd. Having this structure will allow for the sale or IPO of Zenith Epigenetics Ltd or the sale of Resverlogix, but still allow holders of Zenith Capital Corp to benefit from the future royalites that come from Resverlogix or Zenith Epigenetics Ltd. without these royalties being further diluted or sold along with Zenith technology assets.
Make sense? If not, go back to the Agoracom Zenith board for Jan 7-9, 2016 and you can see all the discussion that went on about this after the January 7 AGM.
BearDownAZ